SERS sensing for cancer biomarker: Approaches and directions.

Autor:	Vázquez-Iglesias L; CINBIO, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), 36310, Vigo, Spain., Stanfoca Casagrande GM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil., García-Lojo D; CINBIO, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), 36310, Vigo, Spain., Ferro Leal L; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Medicine Dr. Paulo Prata-FACISB, Barretos, 14785-002, Brazil., Ngo TA; Vinmec Tissue Bank, Vinmec Health Care System, Hanoi, Viet Nam., Pérez-Juste J; CINBIO, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), 36310, Vigo, Spain., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4710-057, Braga, Portugal., Kant K; CINBIO, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), 36310, Vigo, Spain., Pastoriza-Santos I; CINBIO, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.; Galicia Sur Health Research Institute (IIS Galicia Sur), 36310, Vigo, Spain.
Jazyk:	angličtina
Zdroj:	Bioactive materials [Bioact Mater] 2023 Dec 31; Vol. 34, pp. 248-268. Date of Electronic Publication: 2023 Dec 31 (Print Publication: 2024).
DOI:	10.1016/j.bioactmat.2023.12.018
Abstrakt:	These days, cancer is thought to be more than just one illness, with several complex subtypes that require different screening approaches. These subtypes can be distinguished by the distinct markings left by metabolites, proteins, miRNA, and DNA. Personalized illness management may be possible if cancer is categorized according to its biomarkers. In order to stop cancer from spreading and posing a significant risk to patient survival, early detection and prompt treatment are essential. Traditional cancer screening techniques are tedious, time-consuming, and require expert personnel for analysis. This has led scientists to reevaluate screening methodologies and make use of emerging technologies to achieve better results. Using time and money saving techniques, these methodologies integrate the procedures from sample preparation to detection in small devices with high accuracy and sensitivity. With its proven potential for biomedical use, surface-enhanced Raman scattering (SERS) has been widely used in biosensing applications, particularly in biomarker identification. Consideration was given especially to the potential of SERS as a portable clinical diagnostic tool. The approaches to SERS-based sensing technologies for both invasive and non-invasive samples are reviewed in this article, along with sample preparation techniques and obstacles. Aside from these significant constraints in the detection approach and techniques, the review also takes into account the complexity of biological fluids, the availability of biomarkers, and their sensitivity and selectivity, which are generally lowered. Massive ways to maintain sensing capabilities in clinical samples are being developed recently to get over this restriction. SERS is known to be a reliable diagnostic method for treatment judgments. Nonetheless, there is still room for advancement in terms of portability, creation of diagnostic apps, and interdisciplinary AI-based applications. Therefore, we will outline the current state of technological maturity for SERS-based cancer biomarker detection in this article. The review will meet the demand for reviewing various sample types (invasive and non-invasive) of cancer biomarkers and their detection using SERS. It will also shed light on the growing body of research on portable methods for clinical application and quick cancer detection. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu